Anbio Biotechnology (NNNN) is a Frankfurt-based developer of in vitro diagnostic products — lateral flow and fluorescence immunoassays, molecular tests, and point-of-care kits — that listed on Nasdaq in February 2025 at $5.00 per share. In Thursday's session the stock last traded at $3.745, up 4.17%, or roughly $0.15, from the previous close of $3.60. The direction is clearly higher, but after checking company releases, filings, analyst actions, and sector news, no verified fundamental development explains the advance; the move is best characterized as a low-liquidity technical rebound.
No verified news or fundamental catalyst found before the open explains Thursday's gain. The most recent company-specific item was an analyst action: Weiss Ratings cut Anbio to a "Sell (D+)" rating on Nov. 16, and the stock now carries an average analyst stance of "Sell" with minimal coverage. That is a bearish input, not a driver of a 4% advance, and it is too small relative to the company's roughly $165 million market value to justify the move in either direction. Short interest data also offers little help: reported short interest is a fraction of 1% of the float and fell sharply earlier in November, ruling out a squeeze dynamic.
The likelier explanation is mechanical. Anbio routinely moves by several percent a session on tiny turnover, and Thursday's gain follows a failed gap on Wednesday that closed near the session low. That pattern — an intraday fade into the close, followed by dip-buying the next morning — is consistent with speculative, order-driven trading in a thinly traded small cap rather than a repricing of fundamentals. A single modest buy order can move the print several percentage points when the book is thin.
Volume was not elevated. Recent sessions have changed hands in a range of roughly 10,000 to 40,000 shares, well below the trailing average near 150,000 that was inflated by one outsized session in August. Thursday's turnover looked similarly light, so the percentage move overstates the amount of capital involved.
The move also appears idiosyncratic rather than sector-driven. On the stock's previous large up day — Nov. 6, when it gained 8.4% — healthcare benchmarks were essentially flat, and Anbio has repeatedly decoupled from the broader diagnostics group. From a technical standpoint, the shares are back at their 20-day average near $3.74 while remaining far below the 50-day average around $4.64 and the 200-day average near $15.90, both of which are still declining. The stock has not closed above $4.00 since Nov. 11, making that level the first real test of whether this bounce has legs.
The score runs from 0 — no meaningful news and a move that is normal for the stock — to 100, which would require transformative news alongside an extreme, rare price move. Anbio earns 11 out of 100. The verified news flow is weak: a routine ratings downgrade and minor short-interest changes, none material to a company of this size. The price move is equally unremarkable in context. Thursday's 4.17% gain is roughly 1.0 times the stock's average absolute daily move of about 4.0% over the past 60 sessions, and moves of that size or larger occurred more than 20 times in that window. Weak catalyst and ordinary volatility combine into a low score.
No dated earnings event sits on the near-term calendar, and as a foreign private issuer Anbio reports on a limited cadence, so scheduled financial disclosure is unlikely to arrive soon. Investors will instead focus on regulatory execution in Europe, where continued sales depend on completing In Vitro Diagnostic Regulation registrations as transitional permissions expire, and on order flow from a small group of distributors that account for a large share of revenue. Coverage remains minimal, with a single Sell rating and no consensus price target, which limits the chance of an analyst-driven re-rating. Key risks include persistent cash burn despite reported profitability, reliance on third-party manufacturing, and the thin float that makes double-digit swings routine. The stock remains deep in a downtrend, so rallies have repeatedly failed near the $4.00 area.
Tickeron's Trending AI Robots page curates the automated strategies performing best under current market conditions from a library of hundreds of AI trading bots covering thousands of tickers. Because bots differ widely in strategy, timeframe, performance metrics, and the symbols they trade, the trending list highlights only those showing the strongest recent results. It is a practical starting point for investors who want to compare rule-based approaches side by side. Explore the page to see which bots are leading right now and how their parameters line up with your own plan.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The RSI Oscillator for NNNN moved out of oversold territory on November 02, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 10 similar instances when the indicator left oversold territory. In 10 of the 10 cases the stock moved higher. This puts the odds of a move higher at 90%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for NNNN just turned positive on October 23, 2026. Looking at past instances where NNNN's MACD turned positive, the stock continued to rise in 12 of 13 cases over the following month. The odds of a continued upward trend are 90%.
Following a +2.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where NNNN advanced for three days, in 92 of 96 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NNNN as a result. In 28 of 30 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NNNN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
NNNN broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for NNNN entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. NNNN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.865) is normal, around the industry mean (4.964). P/E Ratio (40.884) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (28.169) is also within normal values, averaging (56.876).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NNNN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry PharmaceuticalsOther